Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study

  • Tannaz Dehpouri Student Research Committee, Mazandaran University of Medical Sciences, Ramsar International Branch, Ramsar, Iran, Islamic Republic of.
  • Ghasem Rahmatpour Rokni | Dr.rokni@yahoo.com Department of Dermatology, Mazandaran University of Medical Sciences, Sari, Iran, Islamic Republic of.
  • Nematollah Ahangar Narenjbon Department of Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran, Islamic Republic of.
  • Mohamad Goldust Department of Dermatology, Mazandaran University of Medical Sciences, Sari, Iran, Islamic Republic of.
  • Paul S. Yamauchi Dermatology Institute and Skin Care Center, Santa Monica, California; Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles, California, United States.
  • Uwe Wollina Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Academic Teaching Hospital of the Technical University of Dresden, Dresden, Germany.
  • Torello Lotti Department of Dermatology, “Guglielmo Marconi” University, Rome, Italy.
  • Leon Kircik Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Vito Giuseppe Di Lernia Dermatology Unit, Santa Maria Nuova-IRCCS Hospital, Reggio Emilia, Italy.
  • Sidharth Sonthalia Skinnocence: The Skin Clinic & Research Center, Gurugram, Haryana; Dermasource India, Gurugram, Haryana, India.
  • Aleksandra Vojvodic Department of Dermatology and Venereology, Military Medical Academy, Belgrade, Serbia.
  • Jacek Szepietowski Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
  • Philippe Bahadoran Department of Dermatology, University Hospital of Nice, Nice, France.
  • Enzo Errichetti Department of Experimental and Clinical Medicine, Institute of Dermatology, University of Udine, Udine, Italy.
  • Carmen Cantisani Department of Dermatology, “Umberto I” Hospital, “Sapienza” University of Rome, Rome, Italy.
  • Laura Atzori Dermatology Clinic, Department Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Elham Rezaee Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of.
  • Zekayi Kutlubay Department of Dermatology, Cerrahpasa Faculty of Medicine, University of Istanbul, Istanbul, Turkey.
  • Burhan Engin Department of Dermatology, Cerrahpasa Faculty of Medicine, University of Istanbul, Istanbul, Turkey.
  • Steven Nisticò Department of Health Sciences, “Magna Graecia” University of Catanzaro, Catanzaro, Italy.
  • Giovanni Damiani Department of Medical and Surgical Pathophysiology and Transplantation, University of Milan, Dermatology Unit, IRCCS Ca’ Granda Foundation, Ospedale Maggiore Policlinico, Milan; Young Dermatologists Italian Network (YDIN), Centro Studi GISED, Bergamo, Italy.
  • Rosalynn R.Z. Conic Department of Dermatology, Case Western Reserve University, Cleveland, OH, United States.
  • Andy Goren Department of Dermatology, “Guglielmo Marconi” University, Rome, Italy.
  • Leo Čabrijan Department of Dermatovenereology, Rijeka Clinical Hospital Center, Rijeka, Croatia.
  • Georgi Tchernev Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.

Abstract

Methotrexate (MTX) is a systemic immunosuppressant drug used for the treatment of psoriasis and psoriatic arthritis. Previous studies demonstrated a potential association between psoriasis and diabetes mellitus, obesity, atherosclerosis, hypertension, eventuating into metabolic syndrome. This study aimed at exploring the glycemic effects of MTX in psoriatic arthritis (PsA) patients. In this prospective cross-sectional study, 27 patients with PsA were evaluated. The status of PsA and presence of accompanying metabolic syndrome was determined by standard criteria and indices. Blood indicators including HbA1c, erythrocyte sedimentation rate, fasting blood sugar, total cholesterol, high-density lipoprotein, triglycerides, and C-reactive protein were examined before and 12 weeks after MTX therapy. There were no significant changes between HbA1c levels before and after MTX therapy in both genders (men: P=0.131, women: P=0.803). In addition, HbA1c levels in PsA patients with metabolic syndrome were not different before and after treatment (P=0.250). Finally, HbA1c levels did not change in PsA patients without metabolic syndrome before and after therapy (P=0.506). MTX in PsA patients does not appear to have hyperglycaemic effects in the short-term and can be safely used in patients with metabolic syndrome and diabetes.

Downloads

Download data is not yet available.
Published
2019-05-09
Section
Articles
Keywords:
Psoriatic arthritis, Metabolic syndrome, HbA1c, Methotrexate
Statistics
Abstract views: 422

PDF: 185
HTML: 23
Share it
Bookmark and Share

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Dehpouri, T., Rahmatpour Rokni, G., Ahangar Narenjbon, N., Goldust, M., Yamauchi, P., Wollina, U., Lotti, T., Kircik, L., Di Lernia, V. G., Sonthalia, S., Vojvodic, A., Szepietowski, J., Bahadoran, P., Errichetti, E., Cantisani, C., Atzori, L., Rezaee, E., Kutlubay, Z., Engin, B., Nisticò, S., Damiani, G., Conic, R., Goren, A., Čabrijan, L., & Tchernev, G. (2019). Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatology Reports, 11(1). https://doi.org/10.4081/dr.2019.7965